SGN-TUC-016: A randomized, double-blind, phase 3 study of Tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
The purpose of this study is to test if tucatinib plus T-DM1 works better to treat breast cancer than T-DM1 alone.
Principal Investigator
William MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd, Suite 201
Newport News, VA 23601
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Status
Recruiting
Category
Oncology
Study #